CD19 and systemic lupus erythematosus: In 2022, all five refractory SLE patients receiving anti‐CD19 CAR‐T‐cell therapy achieved B‐cell depletion, decreased anti‐dsDNA antibodies, ameliorated clinical signs and renal involvement, and more importantly, achieved remission at 3 months post CAR‐T‐cell therapy, which even persisted through a median 8‐month follow‐up despite B‐cell recovery [183].